aTyr Pharma Strengthens Board of Directors with the Appointment of Two New Members
July 01, 2019 08:00 ET
|
aTyr Pharma, Inc.
SAN DIEGO, July 01, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological...
aTyr Pharma Announces First Quarter 2019 Results and Provides Corporate Update
May 13, 2019 16:05 ET
|
aTyr Pharma, Inc.
Phase 1b/2a proof-of-concept clinical trial of ATYR1923 in pulmonary sarcoidosis patients ongoing Advanced lead position in Neuropilin-2 (NRP-2) biology with inaugural NRP-2 summit Company to host...
aTyr Pharma to Announce First Quarter 2019 Results on May 13th
May 06, 2019 16:58 ET
|
aTyr Pharma, Inc.
SAN DIEGO, May 06, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological...
aTyr Pharma to Host Inaugural Summit Meeting on Neuropilin-2 (NRP-2) Biology
April 16, 2019 08:00 ET
|
aTyr Pharma, Inc.
SAN DIEGO, April 16, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel...
aTyr Pharma Announces $5 Million Registered Direct Offering led by The Federated Kaufmann Small Cap Fund
April 11, 2019 08:00 ET
|
aTyr Pharma, Inc.
SAN DIEGO, April 11, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel...
aTyr Pharma to Present Poster at the American Thoracic Society 2019 International Conference
April 08, 2019 16:00 ET
|
aTyr Pharma, Inc.
SAN DIEGO, April 08, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel...
aTyr Pharma Announces Fourth Quarter and Full Year 2018 Results and Provides Corporate Update
March 25, 2019 16:00 ET
|
aTyr Pharma, Inc.
Phase 1b/2a proof-of-concept clinical trial of ATYR1923 in pulmonary sarcoidosis patients initiated in December 2018 First tRNA synthetase partnership announced in March 2019 SAN DIEGO,...
aTyr Pharma Announces Poster Presentation at the 2019 American Association for Cancer Research (AACR) Annual Meeting
March 21, 2019 08:00 ET
|
aTyr Pharma, Inc.
SAN DIEGO, March 21, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel...
aTyr Pharma to Announce Fourth Quarter and Full Year 2018 Financial Results on March 25th
March 18, 2019 16:46 ET
|
aTyr Pharma, Inc.
SAN DIEGO, March 18, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel...
aTyr Pharma Announces Research Collaboration With Global Biotherapeutics Leader CSL Behring
March 11, 2019 08:00 ET
|
aTyr Pharma, Inc.
Partnership to accelerate development of IND candidates from tRNA synthetases in aTyr’s pipeline aTyr eligible to receive up to $17 million in potential option fees SAN DIEGO, March 11, 2019 ...